CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of positive Phase 2 interim results for the intracavitary delivery of its anti-cancer compound 131I-TM-601 in recurrent malignant glioma at the Society for Neuro-Oncology’s 12th Annual Scientific Meeting in Dallas, TX. An interim efficacy analysis from the ongoing, open-label Phase 2 safety and efficacy study demonstrated that the overall survival from the time of recurrence for the highest dosing regimen was estimated at 12.1 months, versus 9.0 months for the lowest dose group. Additionally, no dose-limiting toxicities were observed in the dose-escalation phase of the study. The abstract was presented by lead author Dr. Burt Nabors, M.D., of the University of Alabama at Birmingham in a poster session on November 17, 2007.
